Obio Technology (shanghai) (SHSE:688238) ROCE % : -13.94% (As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Obio Technology (shanghai) ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Obio Technology (shanghai)'s annualized ROCE % for the quarter that ended in Sep. 2024 was -13.94%.

Obio Technology (shanghai) ROCE % Historical Data

The historical data trend for Obio Technology (shanghai)'s ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Obio Technology (shanghai) ROCE % Chart

Obio Technology (shanghai) Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-34.35

17.17

6.19

2.58

-6.47

Obio Technology (shanghai) Quarterly Data
	Jun18	Dec18	Jun19	Dec19	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															-5.20	-11.38	-8.67	-10.97	-13.94

Obio Technology (shanghai) ROCE % Calculation

Obio Technology (shanghai)'s annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-148.774	/	( ( (2496.471 - 186.934)	+	(2603.492 - 314.171) )	/ 2 )
	=	-148.774	/	( (2309.537	+	2289.321)	/ 2 )
	=	-148.774	/	2299.429
	=	-6.47 %

Obio Technology (shanghai)'s ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	-294.304	/	( ( (2482.515 - 323.984)	+	(2353.301 - 289.945) )	/ 2 )
	=	-294.304	/	( ( 2158.531	+	2063.356 )	/ 2 )
	=	-294.304	/	2110.9435
	=	-13.94 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Obio Technology (shanghai) (SHSE:688238) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Obio Technology (shanghai) ROCE % Related Terms

Thank you for viewing the detailed overview of Obio Technology (shanghai)'s ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Obio Technology (shanghai) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Obio Technology (shanghai) Corp Ltd (SHSE:688238) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Lane 908, Ziping Road, Building 19, International Medical Park, Pudong New Area, Shanghai, CHN, 201321

Website

https://www.obiosh.com

Obio Technology (shanghai) Corp Ltd is a biotechnology company focusing on the field of gene therapy, focusing on the development of gene therapy vectors, gene function research, drug targets and efficacy for the basic research of gene therapy Research and other CRO services, and provide CDMO services such as process development and testing, IND-CMC pharmaceutical research, and clinical sample GMP production for the research and development of genetic drugs.

Executives

You Qing Rui	Directors, senior managers
Pan Jun Yi	Director
Yang Jia Li	Core technical personnel

Obio Technology (shanghai) Headlines

No Headlines